Ranibizumab antibody | AbD29858
Human anti Ranibizumab
Anti-Ranibizumab Antibody is a recombinant, non-inhibitory, anti-idiotypic antibody in monovalent Fab format for use in a PK antigen capture assay for ranibizumab and its biosimilars.
- Product Type
- Monoclonal Antibody
- HuCAL Fab monovalent
|Product Code||Applications||Pack Size||List Price||Quantity|
Clone AbD29858 can be used to develop a pharmacokinetic (PK) antigen capture format assay to measure free ranibizumab that has been captured via immobilized VEGF-A.
Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.
View a summary of all anti-ranibizumab antibodies
- Product Form
- A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
- Metal chelate affinity chromatography
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- The monovalent intrinsic affinity of AbD29858 was measured as KD=18 nM by real time, label-free molecular interaction analysis on immobilized VEGF/ranibizumab complex.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Lucentis is a trademark of Genentech
His-tag is a trademark of EMD Biosciences.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- For research purposes only
Applications of Ranibizumab antibody
|Application Name||Verified||Min Dilution||Max Dilution|
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Clone AbD29858 can be used in a direct or indirect ELISA on ranibizumab or as a detection reagent for free ranibizumab captured via immobilized VEGF-A.
Protocol: PK antigen capture ELISA to measure free drug